Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: mumbles who wrote (5194)	8/19/1998 8:04:00 PM
From: mumbles	Respond to of 6136

P.S. I was on the Chiron thread several years ago when the same sort of takeover speculation occurred. Some guy posted that Chirons execs were meeting right then at Ed Penhoet's residence re being acquired. He said he knew someone that worked for the company. He then disappeared from the boards. I thought it was hype all the way. One week later, the acquisition (51%) happened. Moral of the story: Sometimes even hype is what actually happens. It makes at least as much sense now as it did for Chiron back then.

To: mumbles who wrote (5194)	8/19/1998 8:42:00 PM
From: JimieA	Respond to of 6136

I also was suspicious that Hoffman LaRoche's termination of their collaboration on AGPH's cancer drugs reduced the appeal of those drugs as potential blockbuster drugs. And therefore has reduced the appeal of AGPH as an investment. Although this has been reflected in AGPH's steady price decline since the beginning of the year. That along with the PI bad press at the recent AIDS conference has pushed the stock price down. But, I could be wrong.